

## **Product Data Sheet**

## **LEAF™ Purified anti-human GM-CSF**

Catalog # / Size: 502203 / 50 µg

502204 / 500 µg

Clone: BVD2-23B6 **Isotype:** Rat IgG2a, κ

Immunogen: E. coli -expressed, recombinant human GM-CSF

Reactivity: Human

Preparation: The LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity

chromatography.

Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no


preservative. Endotoxin level is <0.1 EU/µg of the protein (<0.01 ng/µg of the

protein) as determined by the LAL test.

Concentration: 1.0 mg/ml

Storage: The antibody solution should be stored undiluted at 4°C. This LEAF™ solution

contains no preservative; handle under aseptic conditions.



## **Applications:**

Applications: ELISA Capture - Quality tested ELISPOT Capture, Neut, IP, WB - Reported in the literature

Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration

range of 0.25-1 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of GM-CSF recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be

titrated for optimal performance for each application.

Application Notes: ELISA or ELISPOT Capture<sup>1-6</sup>: The Purified BVD2-23B6 antibody is useful as the capture antibody in a sandwich

ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD2-21C11 antibody (Cat. No. 502304) as

the detecting antibody. The LEAF<sup>TM</sup> Purified antibody is suggested for ELISPOT capture.

Neutralization<sup>1-4</sup>: The LEAF<sup>TM</sup> Purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended

for neutralization of human GM-CSF bioactivity (Cat. No. 502204).

Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>3</sup> and Western blotting. Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 432001 to 432006)

are specially developed and recommended.

1. Bacchetta R, et al. 1990. J. Immunol. 144:902. Application References:

2. Kita H, et al. 1991. J. Exp. Med. 174:745.

3. Abrams J, et al. 1992. Immunol. Rev. 127:5.

4. Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133. 5. Mahanty S, et al. 1992. J. Immunol. 148:3567.

6. Klinman D, et al. 1994. Curr. Prot. Immunol.. John Wiley and Sons New York. Unit 6.19.

Description: Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated

T cells, B cells, mast cells, macrophages, fibroblasts and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte and eosinophil progenitors. The BVD2-23B6 antibody reacts with human granulocyte/macrophage - colony stimulating factor (GM-CSF). The BVD2-23B6 antibody can neutralize the bioactivity of natural or recombinant GM-CSF.

Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.

2. Demetri G, *et al.* 1991. *Blood* 78:2791. 3. Fan D, *et al.* 1991. *In vivo* 5:571.

4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.

**Related Products: Product** 

Recombinant Human GM-CSF

LEAF™ Purified Rat IgG2a, κ Isotype Ctrl

Clone rh GM-CSF

RTK2758

Application BA, ELISA

FC, ICFC, WB, IP, ICC, IF,

IHC, FA



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

